Lenalidomide decreased the <scp>PSA</scp> level for castration‐resistant prostate cancer: a case report

Shimokihara, Kota; Kawahara, Takashi; Suzuki, Taisei; Mochizuki, Takashi; Takamoto, Daiji; Teranishi, Jun‐ichi; Miyoshi, Yasuhide; Yumura, Yasushi; Yao, Masahiro; Uemura, Hiroji

doi:10.1002/ccr3.1328

Clinical Case Reports

2018

DOI: 10.1002/ccr3.1328

|View full text |Cite

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Kota Shimokihara

Takashi Kawahara

Taisei Suzuki

et al.

Abstract: Key Clinical MessageLenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer

Kim¹,

Kim²,

Oh³

2019

Front. Oncol.

View full text Add to dashboard Cite

Purpose: Most prostate cancers (PCs) initially respond to androgen deprivation therapy (ADT), but eventually many PC patients develop castration resistant PC (CRPC). Currently, available drugs that have been approved for the treatment of CRPC patients are limited. Computational drug repositioning methods using public databases represent a promising and efficient tool for discovering new uses for existing drugs. The purpose of the present study is to predict drug candidates that can treat CRPC using a computational method that integrates publicly available gene expression data of tumors from CRPC patients, drug-induced gene expression data and drug response activity data. Methods: Gene expression data from tumoral and normal or benign prostate tissue samples in CRPC patients were downloaded from the Gene Expression Omnibus (GEO) and differentially expressed genes (DEGs) in CRPC were determined with a meta-signature analysis by a metaDE R package. Additionally, drug activity data were downloaded from the ChEMBL database. Furthermore, the drug-induced gene expression data were downloaded from the LINCS database. The reversal relationship between the CRPC and drug gene expression signatures as the Reverse Gene Expression Scores (RGES) were computed. Drug candidates to treat CRPC were predicted using summarized scores (sRGES). Additionally, synergic effects of drug combinations were predicted with a Target Inhibition interaction using the Minimization and Maximization Averaging (TIMMA) algorithm. Results: The drug candidates of sorafenib, olaparib, elesclomol, tanespimycin, and ponatinib were predicted to be active for the treatment of CRPC. Meanwhile, CRPC-related genes, in this case MYL9, E2F2, APOE , and ZFP36 , were identified as having gene expression data that can be reversed by these drugs. Additionally, lenalidomide in combination with pazopanib was predicted to be most potent for CRPC. Conclusion: These findings support the use of a computational reversal gene expression approach to identify new drug and drug combination candidates that can be used to treat CRPC.

show abstract

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer

Kim¹,

Kim²,

Oh³

2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report

Abstract: Key Clinical MessageLenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.

Cited by 1 publication

References 14 publications

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer

Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer

Contact Info

Product

Resources

About